• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
Share
Announcements, News

ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19

December 10, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been awarded a high impact Innovate UK grant as part of the recent “UKRI Ideas to Address COVID-19” competition.  The company will immediately initiate the £390,000 project, which will be co-funded by Innovate UK, to develop novel protease biomarkers to identify high-risk patients.

Speaking about the plans, Dr David Ribeiro, CEO of ProAxsis, said:

“Recognition of this kind from Innovate UK, the UK’s innovation agency, is an enormous testament to the cutting-edge research being conducted by the ProAxsis team of scientists at its purpose-built laboratory in Belfast.  This project is targeted at utilising the company’s unprecedented expertise in active protease biomarkers to enable clinicians to identify which patients are at highest risk of experiencing significant symptoms when they become infected with COVID-19, as well as creating novel diagnostic tools for measuring the effectiveness of potential therapies.  This award will drive significant expansion of the company’s R&D activities and builds on our existing work on inflammatory biomarkers associated with COVID-19.”

Dr Ribeiro added:

“The awarding of this grant, alongside the strong support of our investors, Netscientific plc, has enabled the company to immediately expand its team in Belfast with the recruitment of additional R&D scientists.  As a first step, we welcome Ciaran McGranaghan, who recently graduated with a First Class Honours degree in Biological Sciences from Queen’s University Belfast.”

Gavin Robinson, MP for Belfast East, said: “Last week we received positive news that the UK would be rolling out a vaccine this side of Christmas. I’m delighted that this week, ProAxsis based in East Belfast have been successful in their application for an Innovate UK grant. A huge congratulations to the dedicated team for this notable achievement.”

Any enquiries concerning ProAxsis’ work on COVID-19 can be directed to info@proaxsis.com.

About ProAxsis

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

About Innovate UK

Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new areas.  We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth.

We fund business and research collaborations to accelerate innovation and drive business investment into R&D.  Our support is available to businesses across all economic sectors, value chains and UK regions.

Innovate UK is part of UK Research and Innovation.  For more information, please visit www.innovateuk.ukri.org

December 10, 2020

Related News

Other posts that you should not miss.
NEATstik®, News

ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

September 4, 2017
-
Posted by Webmaster

ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care …

Read More
September 4, 2017
Posted by Webmaster
News

ProAxsis announces new appointments

June 23, 2020
-
Posted by David Ribeiro

ProAxsis Limited, the Belfast-based diagnostics company, is pleased to welcome back Elisha Cain, who re-joins the company …

Read More
June 23, 2020
Posted by David Ribeiro
News

ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test

May 16, 2022
-
Posted by Jessica Robinson

ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, has successfully completed the Performance Evaluation study of the …

Read More
May 16, 2022
Posted by Jessica Robinson
← PREVIOUS POST
ProAxsis Limited appoints first distributor for DACH region
NEXT POST →
ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • July 26, 2022
    ProAxsis announces additional key appointments
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19 - ProAxsis